Excited to share our Valar Labs publication in European Urology validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…

We are pleased to share our new publication in European Urology validating Vesta Risk Stratify biomarkers for prediction of recurrence and progression in High Grade Ta Bladder Cancer. Press Release: businesswire.com/news/home/2025… Grateful to all the collaborators involved and

Listen to hear how AI is being used to discover new drug applications by through repurposing existing drugs for rare diseases and more

The first results from the Phase III #RADCOMP trial ASTRO — the first randomized trial of proton vs photon therapy for breast cancer. 📌 Focus: Health-related quality of life outcomes. 📍 Monday Sept 29| 1:30 PM PT | San Francisco Ballroom #BreastCancer #ProtonTherapy

Career opportunities and leadership outside the clinic with ASTRO Novartis Kiran Devisetty, MD, FASTRO Trevor J. Royce MD MPH FASCO #radonc #md #medicine #industry #pharma ARRO instagram.com/stories/alexna…

Come see our first panel for career opportunities and leadership outside of the clinic, happening now! Thank you to our panelists pictured below!

Coming to #ASTRO25 ? Check out our educational session on Multi-Disciplinary Management of #BladderCancer 🗓️ Monday, September 29, 2025 ⏱️ 10:45 AM - 12:00 PM 📍Room 155/157 Hear the latest updates from: Leslie Ballas Jonathan L Wright Rosa Nadal Brian C. Baumann ASTRO

Thanks for having us! Cc Sushil For the audience: don’t hesitate to reach out with any follow up questions!

We show in our study that SBRT and IMRT courses can be enriched for thoracic RT and curative intent RT courses using a simple classification algorithm. 3DCRT also is classifiable, but more non-thoracic and palliative courses are misclassified. Drew Moghanaki Salma Jabbour